BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine 2015;11:1097-107. [PMID: 25752855 DOI: 10.1016/j.nano.2015.02.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ong HK, Tan WS, Ho KL. Virus like particles as a platform for cancer vaccine development. PeerJ 2017;5:e4053. [PMID: 29158984 DOI: 10.7717/peerj.4053] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
2 Heider S, Reimhult E, Metzner C. Real-time analysis of protein and protein mixture interaction with lipid bilayers. Biochimica et Biophysica Acta (BBA) - Biomembranes 2018;1860:319-28. [DOI: 10.1016/j.bbamem.2017.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 Metzner C, Salmons B, Günzburg WH, Dangerfield JA. Comment on Patel et al; "Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses" Nanomedicine, 2015. 11(5): p. 1097-107. Nanomedicine 2016;12:665-6. [PMID: 26593637 DOI: 10.1016/j.nano.2015.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Quan FS, Lee YT, Kim KH, Kim MC, Kang SM. Progress in developing virus-like particle influenza vaccines. Expert Rev Vaccines 2016;15:1281-93. [PMID: 27058302 DOI: 10.1080/14760584.2016.1175942] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
5 Bommireddy R, Stone S, Bhatnagar N, Kumari P, Munoz LE, Oh J, Kim KH, Berry JTL, Jacobsen KM, Jaafar L, Naing SH, Blackerby AN, Gaag TV, Wright CN, Lai L, Pack CD, Ramachandiran S, Suthar MS, Kang SM, Kumar M, Reddy SJC, Selvaraj P. Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. Vaccines (Basel) 2022;10:944. [PMID: 35746552 DOI: 10.3390/vaccines10060944] [Reference Citation Analysis]
6 Liu J, Ren Z, Wang H, Zhao Y, Wilker PR, Yu Z, Sun W, Wang T, Feng N, Li Y, Wang H, Ji X, Li N, Yang S, He H, Qin C, Gao Y, Xia X. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses. Int Immunopharmacol 2018;63:119-28. [PMID: 30081250 DOI: 10.1016/j.intimp.2018.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee KL, Twyman RM, Fiering S, Steinmetz NF. Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016;8:554-78. [PMID: 26782096 DOI: 10.1002/wnan.1383] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
8 Pack CD, Bommireddy R, Munoz LE, Patel JM, Bozeman EN, Dey P, Radhakrishnan V, Vartabedian VF, Venkat K, Ramachandiran S, Reddy SJC, Selvaraj P. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Hum Vaccin Immunother 2020;16:3184-93. [PMID: 32530786 DOI: 10.1080/21645515.2020.1754691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xu X, Ding Z, Li J, Liang J, Bu Z, Ding J, Yang Y, Lang X, Wang X, Yin R, Qian J. Newcastle disease virus-like particles containing the Brucella BCSP31 protein induce dendritic cell activation and protect mice against virulent Brucella challenge. Vet Microbiol 2019;229:39-47. [PMID: 30642597 DOI: 10.1016/j.vetmic.2018.12.007] [Reference Citation Analysis]
10 Quan FS, Basak S, Chu KB, Kim SS, Kang SM. Progress in the development of virus-like particle vaccines against respiratory viruses. Expert Rev Vaccines 2020;19:11-24. [PMID: 31903811 DOI: 10.1080/14760584.2020.1711053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Heider S, Dangerfield JA, Metzner C. Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res 2016;57:1778-88. [PMID: 27542385 DOI: 10.1194/jlr.R070201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Heider S, Kleinberger S, Kochan F, Dangerfield JA, Metzner C. Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59. Mol Biotechnol 2016;58:480-8. [PMID: 27170144 DOI: 10.1007/s12033-016-9944-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Matabaro E, He Z, Liu YS, Zhang HJ, Gao XD, Fujita M. Molecular switching system using glycosylphosphatidylinositol to select cells highly expressing recombinant proteins. Sci Rep 2017;7:4033. [PMID: 28642584 DOI: 10.1038/s41598-017-04330-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Front Immunol 2021;12:786617. [PMID: 34868073 DOI: 10.3389/fimmu.2021.786617] [Reference Citation Analysis]